64. Skeletal Effects of Drugs

  1. Clifford J. Rosen MD
  1. Juliet Compston

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch64

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

Compston, J. (2013) Skeletal Effects of Drugs, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch64

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • acid-suppressive medications;
  • androgen deprivation therapy (ADT);
  • antiepileptic drugs;
  • antihormonal drugs;
  • glucocorticoids;
  • osteoporosis;
  • skeletal effects;
  • thiazolidenediones (TZDs)

Summary

Iatrogenic bone loss, caused by therapies for nonskeletal diseases, is a growing and important cause of osteoporosis. Drugs that have been implicated include aromatase inhibitors, androgen deprivation therapy (ADT), and thiazolidenediones (TZDs). In contrast, some interventions for nonskeletal diseases can be protective to the skeleton. This chapter focuses on drugs, namely, glucocorticoids, antihormonal drugs, thiazolidinediones, proton pump inhibitors, heparin, anticonvulsants, calcineurin inhibitors, thyroxine, chemotherapy, and selective serotonin reuptake inhibitors. Drugs that may have protective skeletal effects are also considered.